INT23834

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.55
First Reported 1983
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 3.79
Pain Relevance 1.15

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (AKR1B1) carbohydrate metabolic process (AKR1B1) response to stress (AKR1B1)
cytoplasm (AKR1B1) cytosol (AKR1B1) extracellular space (AKR1B1)
Anatomy Link Frequency
Caco-2 1
sensory nerve 1
AKR1B1 (Homo sapiens)
Pain Link Frequency Relevance Heat
diabetic neuropathy 14 99.60 Very High Very High Very High
Painful diabetic neuropathy 2 99.48 Very High Very High Very High
cINOD 2 98.32 Very High Very High Very High
agonist 11 97.84 Very High Very High Very High
Neuropathic pain 2 93.68 High High
Pain 5 89.04 High High
withdrawal 2 66.44 Quite High
Kinase C 4 61.68 Quite High
cytokine 14 61.56 Quite High
Inflammation 59 60.12 Quite High
Disease Link Frequency Relevance Heat
Adverse Drug Reaction 19 100.00 Very High Very High Very High
Colon Cancer 7 99.92 Very High Very High Very High
Diabetic Neuropathy 10 99.60 Very High Very High Very High
INFLAMMATION 63 98.08 Very High Very High Very High
Adhesions 8 97.44 Very High Very High Very High
Neuropathic Pain 15 93.68 High High
Pain 5 89.04 High High
Stress 19 88.96 High High
Diabetes Mellitus 69 87.56 High High
Myocardial Infarction 2 86.64 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pharmacological inhibition of aldose reductase in human diabetic neuropathy.
Negative_regulation (inhibition) of aldose reductase associated with diabetic neuropathy
1) Confidence 0.55 Published 1986 Journal Drugs Section Title Doc Link 2431859 Disease Relevance 0.29 Pain Relevance 0.22
A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy.
Negative_regulation (inhibitor) of aldose reductase associated with painful diabetic neuropathy
2) Confidence 0.43 Published 1983 Journal Diabetes Section Title Doc Link 6225686 Disease Relevance 0.36 Pain Relevance 0.39
SELECTION CRITERIA: We included randomized controlled trials comparing an aldose reductase inhibitor with control, and lasting at least six months.
Negative_regulation (inhibitor) of aldose reductase
3) Confidence 0.42 Published 2007 Journal Cochrane Database Syst Rev Section Body Doc Link 17943821 Disease Relevance 0.08 Pain Relevance 0
Studies of the effect of sorbinil, an aldose reductase inhibitor, in human diabetic neuropathy have shown improvements in motor and sensory nerve conduction velocity and somatosensory evoked potentials, and a reduction in neuropathic pain.
Negative_regulation (inhibitor) of aldose reductase in sensory nerve associated with diabetic neuropathy and neuropathic pain
4) Confidence 0.41 Published 1986 Journal Drugs Section Abstract Doc Link 2431859 Disease Relevance 0.27 Pain Relevance 0.18
Inhibition of aldose reductase (AR; EC. 1.1.1.21.) by sorbinil or by antisense ablation prevented fibroblast growth factor-induced and platelet-derived growth factor-induced up-regulation of PGE(2) synthesis in human colon cancer cells, Caco-2.
Negative_regulation (Inhibition) of aldose reductase in Caco-2 associated with colon cancer
5) Confidence 0.29 Published 2006 Journal Cancer Res. Section Abstract Doc Link 17018629 Disease Relevance 0.37 Pain Relevance 0.19
When compared to atosiban, the number needed to prevent one serious ADR for ?
Negative_regulation (prevent) of ADR associated with adverse drug reaction
6) Confidence 0.09 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971730 Disease Relevance 1.36 Pain Relevance 0.05
Aldose reductase inhibitors and the polyol pathway
Negative_regulation (inhibitors) of Aldose reductase
7) Confidence 0.05 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350125 Disease Relevance 0.37 Pain Relevance 0.09
Sorbinil and zenarestat are orally active aldose reductase inhibitors (ARI's) derived from quinazoline.
Negative_regulation (inhibitors) of aldose reductase
8) Confidence 0.03 Published 2009 Journal J Transl Med Section Body Doc Link PMC2666642 Disease Relevance 0.71 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox